RxDoctor Payments Data

George Heyrich, MD

Interventional Cardiology · Newtown, PANPI 1316938707

Payments from drug & device makers

$48,869in general payments, 2019–2025

Across 417 payments — averaging $117.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$22K
  • Boston Scientific$7K
  • Medtronic$7K
  • Pfizer$6K
  • Edwards Lifesciences$5K
  • Abiomed$703
  • plus $2K from 21 others
$2,000in research payments, 2019–2025

Across 1 payment — averaging $2000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$2K

What the payments were for

  • Consulting fees$5,02515%
  • Speaking & faculty fees$5,25016%
  • Travel & lodging$6,60920%
  • Food & beverage$16,46049%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$48,869 in reported general payments places this provider in the 75th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$316,542
Medicare patients
831
Services billed
2,842

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban428$500,866
EntrestoSacubitril/Valsartan101$151,106
XareltoRivaroxaban34$45,618
Repatha SureclickEvolocumab64$44,609
BrilintaTicagrelor32$32,493
Praluent PenAlirocumab14$18,531
NexletolBempedoic Acid20$16,444
MultaqDronedarone Hcl12$13,126
Metoprolol Succinate747$12,487
Pitavastatin Calcium19$11,179
Dofetilide26$10,702
Icosapent Ethyl25$10,410
Rosuvastatin Calcium623$10,062
Atorvastatin Calcium620$8,798
Losartan Potassium543$6,764

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$5,793$500,866428 claims
NovartisEntresto$158$151,106101 claims
Johnson & JohnsonXarelto$290$45,61834 claims
AstraZenecaBrilinta$334$32,49332 claims
Sanofi-aventis U.S. LLCMultaq$58$13,12612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 281 interventional cardiology providers in Pennsylvania.

Other interventional cardiology in Newtown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →